Key result
Pharmacogenetic-guided antiplatelet therapy was the preferred strategy for ACS patients undergoing PCI, yielding the lowest cost (US$75,208) and highest QALYs gained.
Why the study?
Does pharmacogenetic-guided antiplatelet therapy improve cost-effectiveness compared to other antiplatelet strategies in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Does pharmacogenetic-guided antiplatelet therapy improve cost-effectiveness compared to other antiplatelet strategies in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
Pharmacogenetic-guided antiplatelet therapy appears to be the most cost-effective strategy for patients with acute coronary syndrome undergoing PCI.
AIM: This study aimed to compare the clinical and economic outcomes of pharmacogenetic-guided (PG-guided) and platelet reactivity testing-guided antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention. METHODS: A decision-analytic model was simulated including four antiplatelet strategies: universal clopidogrel 75 mg daily, universal alternative P2Y12 inhibitor (prasugrel or ticagrelor), PG-guided therapy, and platelet reactivity testing-guided therapy. RESULTS: PG-guided therapy was the preferred option with lowest cost (US$75,208) and highest quality-adjusted life years gained (7.6249 quality-adjusted life years). The base-case results were robust in sensitivity analysis. CONCLUSION: PG-guided antiplatelet therapy showed the highest probability to be preferred antiplatelet strategy for acute coronary syndrome patients with percutaneous coronary intervention.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2016) studied Acute coronary syndrome. Pharmacogenetic-guided antiplatelet therapy vs. Universal clopidogrel, universal alternative P2Y12 inhibitor, or platelet reactivity testing-guided therapy was evaluated on Clinical and economic outcomes (cost and quality-adjusted life years). Pharmacogenetic-guided antiplatelet therapy was the preferred strategy for ACS patients undergoing PCI, yielding the lowest cost (US$75,208) and highest QALYs gained.
Synapse has enriched 10 related papers. Consider them for comparative context: